Innovative Applications of Nanotechnology and Photothermal Therapy in Cancer Treatment and Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 511

Special Issue Editors


E-Mail Website
Guest Editor
iMed.ULisboa, Research Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
Interests: drug delivery systems; 2D and 3D in vitro models; establishment of murine models and alternative routes of administration; pharmacokinetic and biodistribution studies; bacterial infections; melanoma; breast cancer; inflammation; colon cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
IBEB/FCUL, iMed.ULisboa, Faculty of Pharmacy, University of Lisboa, Lisboa, Portugal
Interests: photothermal therapy; development of new drug delivery systems; methods of micro and nanoencapsulation of drugs; medical devices; food supplements; cosmetics; targeted therapies; in vivo efficacy and safety assessments using animal models; preclinical toxicity assessment; regulatory affairs
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to an upcoming Special Issue of Pharmaceutics titled "Innovative Applications of Nanotechnology and Photothermal Therapy in Cancer Treatment and Drug Delivery". This collection aims to explore the latest developments in nanomedicine, focusing on different nanotechnological approaches, such as photothermal and photodynamic therapies, including a high diversity of drug delivery systems. The special issue will cover the following topics:

- Innovative nanomaterials for photothermal therapy;

- Photodynamic therapy;

- Drug delivery systems;

- Chemotherapy;

- Local and systemic delivery strategies using nanoscale formulations;

- In situ delivery methods for enhanced therapeutic efficacy;

- Design and characterization of novel nanoscale dosage forms;

- Pre-clinical studies evaluating the efficacy and safety of nanomedicine approaches;

- Development of advanced in vitro models for nanomaterial testing;

- Regulatory considerations in the development of nanomaterial-based therapies.

We are please to invite you to submit your original research articles and reviews to be featured in this collection.

This Special Issue aims to showcase recent advancements in different nanotechnological approaches, including photothermal therapy (PTT) and drug delivery systems. Nanomedicine is a valuable research field that allows us to effectively deliver selective drugs, diagnose diseases, and perform imaging using different types of nanomaterials.

One of the key benefits of nanomedicine is its potential to address cancer metastasis, a major challenge in oncology. Furthermore, the combination of PTT with other treatment modalities, such as chemotherapy or photodynamic therapy, has shown promising results in achieving synergistic therapeutic effects against both primary and metastatic tumors. In addition, the development of multifunctional nanoplatforms that integrate imaging capabilities with therapeutic functions will allow for real-time monitoring of treatment progress and improved targeting of cancer cells.  

Contributions may include original research articles, reviews, and perspective pieces that advance our understanding of nanomaterial-based therapies. Research areas may include (but need not be limited to) the following:

- Exploring new nanomaterial compositions for enhanced photothermal effects;

- Investigating synergistic effects of combined photothermal and chemotherapy approaches;

- Developing innovative in situ forming or shear-thinning hydrogels for local delivery;

- Addressing safety and environmental considerations of nanomaterials in healthcare;

- Examining regulatory pathways for nanomedicine products.

We look forward to your valuable contributions to this rapidly evolving field of nanomedicine.

Dr. Maria Manuela Gaspar
Dr. Catarina Pinto Reis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • photothermal therapy
  • drug delivery
  • chemotherapy
  • nanomaterials
  • local and systemic delivery
  • in situ delivery
  • nanoscale dosage forms
  • nanomedicine
  • pre-clinical studies
  • in vitro models
  • regulatory affairs

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 1250 KiB  
Review
Breaking the Resistance: Photodynamic Therapy in Cancer Stem Cell-Driven Tumorigenesis
by Sheeja S. Rajan, J. P. Jose Merlin and Heidi Abrahamse
Pharmaceutics 2025, 17(5), 559; https://doi.org/10.3390/pharmaceutics17050559 - 24 Apr 2025
Viewed by 360
Abstract
Cancer stem cells (CSCs) are essential for the growth of malignancies because they encourage resistance to cancer therapy and make metastasis and relapse easier. To effectively tackle the obstacles presented by CSCs, novel therapeutic approaches are required. Photodynamic therapy (PDT) is a promising [...] Read more.
Cancer stem cells (CSCs) are essential for the growth of malignancies because they encourage resistance to cancer therapy and make metastasis and relapse easier. To effectively tackle the obstacles presented by CSCs, novel therapeutic approaches are required. Photodynamic therapy (PDT) is a promising treatment option for cancer cells, which uses light-sensitive medications that are activated by light wavelengths. This review investigates the use of PDT to overcome malignancies driven by CSCs that have innate resistance mechanisms. PDT works by causing tumor cells to accumulate photosensitizers (PSs) selectively. The reactive oxygen species (ROS), which kill cells, are released by these PSs when they are stimulated by light. According to recent developments in PDT, its efficacy may go beyond traditional tumor cells, providing a viable remedy for the resistance shown by CSCs. Researchers want to improve the targeted elimination and selective targeting of CSCs by combining PDT with new PSs and customized delivery systems. Studies emphasize how PDT affects CSCs as well as bulk tumor cells. According to studies, PDT not only limits CSC growth but also modifies their microenvironment, which lowers the possibility of recovery. Additionally, studies are being conducted on the utilization of PDT and immunotherapeutic techniques to improve treatment efficacy and overcome inherent resistance of CSCs. In conclusion, PDT is a viable strategy for treating carcinogenesis driven by CSCs. By applying the most recent advancements in PDT technologies and recognizing how it interacts with CSCs, this treatment has the potential to surpass traditional resistance mechanisms and improve the future of cancer patients. Clinical and preclinical studies highlight that combining PDT with CSC-targeted approaches has the potential to overcome current therapy limitations. Future efforts should focus on clinical validation, optimizing light delivery and PS use, and developing effective combination strategies to target CSCs. Full article
Show Figures

Figure 1

Back to TopTop